Novo Nordisk has filed for European approval for its long-acting insulin product Degludec and insulin combination analogue DegludecPlus, directly competing with Sanofi’s Lantus.

The Danish pharmaceutical firm has submitted the applications on the basis of results from the BEGIN and BOOST trial programmes, which enrolled almost 10,000 type 1 and type 2 diabetes patients and posted positive results in lowering blood glucose levels.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Degludec also demonstrated a significantly lower rate of hypoglycaemia in comparison to Sanofi’s insulin product Lantus.

Lantus is currently the world’s biggest selling insulin product, responsible for revenues totalling $3.5bn in 2010, but Degludec is expected to be a considerable challenger.

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now